MedPath

Effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRAmUC study)

Not Applicable
Recruiting
Conditions
metastatic urothelial carcinoma
Registration Number
JPRN-UMIN000039881
Lead Sponsor
Hirosaki University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with metastatic urothelial carcinoma who were not treated with standard of care or no frailty evaluation.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome was the effect of frailty on progression-free survival in patients with metastatic urothelial carcinoma
Secondary Outcome Measures
NameTimeMethod
Secondary outcomes included safety, progression-free survival, and overall survival.
© Copyright 2025. All Rights Reserved by MedPath